Published in Proc Natl Acad Sci U S A on June 20, 2000
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A (2006) 1.92
T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci U S A (2004) 1.91
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A (2001) 1.61
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A (2003) 1.46
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A (2005) 1.44
The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol (2012) 1.41
Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest (2001) 1.20
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs (2011) 1.15
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2003) 1.14
Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol (2006) 1.06
Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci (2008) 1.04
Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 1.03
Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS. PLoS One (2011) 1.00
Solving the lost in translation problem: improving the effectiveness of translational research. Curr Opin Pharmacol (2012) 0.98
Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction? Mol Psychiatry (2010) 0.97
Thymic involution, a co-morbidity factor in amyotrophic lateral sclerosis. J Cell Mol Med (2010) 0.91
Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: comparison with other myelin antigens. Proc Natl Acad Sci U S A (2001) 0.91
Neuroprotection in glaucoma. Indian J Ophthalmol (2011) 0.88
Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J Neural Transm (Vienna) (2009) 0.88
Modulation of innate immunity by copolymer-1 leads to neuroprotection in murine HIV-1 encephalitis. Glia (2008) 0.87
Impact of acute inflammation on spinal motoneuron synaptic plasticity following ventral root avulsion. J Neuroinflammation (2010) 0.85
Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death. Am J Pathol (2010) 0.84
ROCKs as immunomodulators of stroke. Expert Opin Ther Targets (2012) 0.84
Involvement of the CD200 receptor complex in microglia activation in experimental glaucoma. Exp Eye Res (2011) 0.83
What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol (2004) 0.83
Multiple sclerosis: overview of disease-modifying agents. Perspect Medicin Chem (2014) 0.82
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study. Malar J (2009) 0.82
Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury. Brain Behav Immun (2013) 0.82
Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders. Cell Mol Neurobiol (2001) 0.79
BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease. PLoS One (2011) 0.79
Neuroprotection in glaucoma. J Ophthalmic Vis Res (2012) 0.78
Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system? Int J Mol Sci (2012) 0.78
Erratum to: Immune maintenance in glaucoma: boosting the body's own neuroprotective potential. J Ocul Biol Dis Infor (2009) 0.77
Immune maintenance in glaucoma: boosting the body's own neuroprotective potential. J Ocul Biol Dis Infor (2009) 0.77
Glatiramer acetate does not protect from acute ischemic stroke in mice. Exp Transl Stroke Med (2014) 0.77
The potential neuroprotective effects of weekly treatment with glatiramer acetate in diabetic patients after panretinal photocoagulation. Clin Ophthalmol (2011) 0.77
Retinal stem cells transplantation combined with copolymer-1 immunization reduces interferon-gamma levels in an experimental model of glaucoma. Int J Ophthalmol (2011) 0.76
Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2007) 0.76
T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment. Sci Rep (2015) 0.75
How and why do T cells and their derived cytokines affect the injured and healthy brain? Nat Rev Neurosci (2017) 0.75
The role of growth factors as a therapeutic approach to demyelinating disease. Exp Neurol (2016) 0.75
Process signatures in glatiramer acetate synthesis: structural and functional relationships. Sci Rep (2017) 0.75
Abstracts of the 13th Meeting of the European Neurological Society. 14-18 June 2003, Istanbul, Turkey. J Neurol (2003) 0.75
T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol (1978) 28.92
T-lymphocyte entry into the central nervous system. J Neurosci Res (1991) 4.28
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol (1981) 3.96
Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med (1999) 3.13
A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes. J Exp Med (1989) 2.85
Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med (1999) 2.84
Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today (1997) 2.44
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1997) 2.00
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol (1971) 1.94
Experimental autoimmune encephalomyelitis (EAE) mediated by T cell lines: process of selection of lines and characterization of the cells. J Immunol (1982) 1.84
Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature (1993) 1.71
Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature (1993) 1.64
Diagnosis and pathogenesis of glaucomatous optic neuropathy: morphological aspects. Prog Retin Eye Res (2000) 1.52
Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci (1999) 1.44
Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol (1998) 1.38
Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med (1997) 1.36
Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol (1996) 1.30
T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur J Immunol (1993) 1.25
Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol (1998) 1.20
Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc Natl Acad Sci U S A (1988) 1.17
The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J Neurol (1996) 1.15
Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet (2000) 1.10
Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol (1998) 1.10
Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J (1999) 1.08
Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J Glaucoma (1996) 0.92
Accumulation of passively transferred primed T cells independently of their antigen specificity following central nervous system trauma. J Neuroimmunol (1998) 0.90
Neuroprotection: a new treatment modality for glaucoma? Curr Opin Ophthalmol (2000) 0.89
Self-destructive and self-protective processes in the damaged optic nerve: implications for glaucoma. Invest Ophthalmol Vis Sci (2000) 0.89
Traumatic optic neuropathy. Curr Opin Ophthalmol (1999) 0.85
Correlation between strain differences in susceptibility to experimental allergic encephalomyelitis and the immune response to encephalitogenic protein in inbred guinea pigs. Immunol Commun (1973) 0.84
Graded crush of the rat optic nerve as a brain injury model: combining electrophysiological and behavioral outcome. Restor Neurol Neurosci (1990) 0.83
Binding of random copolymers of three amino acids to class II MHC molecules. Int Immunol (1999) 0.80
Copolymer 1 from the laboratory to FDA. Isr J Med Sci (1997) 0.79
The UCSC Genome Browser Database. Nucleic Acids Res (2003) 32.84
MINIATURE escherichia coli CELLS DEFICIENT IN DNA. Proc Natl Acad Sci U S A (1967) 19.02
Neisseria gonorrhoeae. II. Colonial variation and pathogenicity during 35 months in vitro. J Bacteriol (1968) 16.77
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet (2001) 11.12
Regulation of tumor antigen synthesis by simain virus 40 gene A. J Virol (1975) 9.93
Exposure measurement error in time-series studies of air pollution: concepts and consequences. Environ Health Perspect (2000) 9.30
Positive control of transcription initiation in bacteria. Annu Rev Genet (1984) 8.74
Isolation of the bacteriophage lambda receptor from Escherichia coli. J Bacteriol (1973) 7.67
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 7.47
Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med (1965) 7.27
Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature (1988) 6.18
Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med (1994) 6.05
Location of the maltose A and B loci on the genetic map of Escherichia coli. J Bacteriol (1966) 5.97
Effects of colchicine and related substances on cell division. Biochem J (1936) 5.80
Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res (2001) 5.78
Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med (2001) 5.48
Absorption of guinea pig serum with agar. A method for elimination of itscytotoxicity for murine thymus cells. Transplantation (1970) 5.37
Maltose transport in Escherichia coli K12. A comparison of transport kinetics in wild-type and lambda-resistant mutants as measured by fluorescence quenching. Eur J Biochem (1976) 5.25
A role for mRNA secondary structure in the control of translation initiation. Nature (1982) 5.01
Mouse actin messenger RNAs. Construction and characterization of a recombinant plasmid molecule containing a complementary DNA transcript of mouse alpha-actin mRNA. J Biol Chem (1981) 4.30
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol (1981) 3.96
Three cdg operons control cellular turnover of cyclic di-GMP in Acetobacter xylinum: genetic organization and occurrence of conserved domains in isoenzymes. J Bacteriol (1998) 3.81
Use of gene fusions to study outer membrane protein localization in Escherichia coli. Proc Natl Acad Sci U S A (1977) 3.78
The adsorption of coliphage lambda to its host: effect of variations in the surface density of receptor and in phage-receptor affinity. J Mol Biol (1976) 3.75
Competition between, and effectiveness of, IgG and IgM antibodies in indirect fluorescent antibody and other tests. J Immunol (1967) 3.72
Natural and immune human antibodies reactive with antigens of virulent Neisseria gonorrhoeae: immunoglobulins G, M, And A. J Bacteriol (1967) 3.56
Genetic analysis of the maltose A region in Escherichia coli. J Bacteriol (1969) 3.52
Escherichia coli mutants impaired in maltodextrin transport. J Bacteriol (1979) 3.51
Dominant constitutive mutations in malT, the positive regulator gene of the maltose regulon in Escherichia coli. J Mol Biol (1978) 3.46
Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet (1991) 3.37
A clinical trial of active management of labor. N Engl J Med (1995) 3.34
[Existence in Escherichia coli K 12 of a common regulation of the biosynthesis of bacteriophage receptors and maltose metabolism]. Ann Inst Pasteur (Paris) (1967) 3.33
Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci U S A (1985) 3.31
Pleiotropic mutations rendering Escherichia coli K-12 resistant to bacteriophage TP1. J Bacteriol (1980) 3.31
Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet (2001) 3.26
T lymphocytes of rheumatoid arthritis patients show augmented reactivity to a fraction of mycobacteria cross-reactive with cartilage. Lancet (1986) 3.20
Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med (1999) 3.13
The localization of antigen in relation to specific antibody-producing cells. I. Use of a synthetic polypeptide [(T,G)-A--L] labelled with iodine-125. Immunology (1966) 3.09
Patterns of polymorphism and linkage disequilibrium for cystic fibrosis. Genomics (1987) 3.03
Natural human antibodies to gram-negative bacteria: immunoglobulins G, A, and M. Science (1966) 3.00
Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. Ann Thorac Surg (1994) 3.00
Structure of the malB region in Escherichia coli K12. I. Genetic map of the malK-lamB operon. Mol Gen Genet (1979) 2.99
Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. Science (1983) 2.96
The properties of DNA transferred to minicells during conjugation. Cold Spring Harb Symp Quant Biol (1968) 2.86
Primary cardiac valve tumors. Ann Thorac Surg (1991) 2.85
[Phenotypic expression and genetic localization of mutations affecting maltose metabolism in Escherichia coli K 12]. Ann Inst Pasteur (Paris) (1967) 2.83
Structure of the malB region in Escherichia coli K12. II. Genetic map of the malE,F,G operon. Mol Gen Genet (1979) 2.83
Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A (1978) 2.78
Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet (2001) 2.70
Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell (1994) 2.69
Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria but not to collagen type II. J Clin Invest (1984) 2.66
Synthesis of linear plasmid multimers in Escherichia coli K-12. J Bacteriol (1986) 2.65
Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun (1988) 2.65
Complementation studies in the maltose-A region of the Escherichia coli K12 genetic map. J Mol Biol (1971) 2.60
malB region in Escherichia coli K-12: characterization of new mutations. J Bacteriol (1974) 2.56
Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med (1996) 2.55
CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Hum Genet (2001) 2.51
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol (1993) 2.49
Intergration of the receptor for bacteriophage lambda in the outer membrane of Escherichia coli: coupling with cell division. J Bacteriol (1975) 2.47
Mutations that affect lamB gene expression at a posttranscriptional level. Proc Natl Acad Sci U S A (1981) 2.46
Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature (1981) 2.44
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
Synovial fluid T cell reactivity against 65 kD heat shock protein of mycobacteria in early chronic arthritis. Lancet (1988) 2.43
Genetic control of the antibody response. II. Further analysis of the specificity of determinant-specific control, and genetic analysis of the response to (H,G)-A--L in CBA and C57 mice. J Exp Med (1967) 2.41
Antigenicity of some new synthetic polypeptides and polypeptidyl gelatins. Biochem J (1964) 2.40
Mutations altering the cellular localization of the phage lambda receptor, an Escherichia coli outer membrane protein. Proc Natl Acad Sci U S A (1978) 2.37
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res (2000) 2.33
Studies of RFLP closely linked to the cystic fibrosis locus throughout Europe lead to new considerations in populations genetics. Hum Genet (1990) 2.33
Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med (1998) 2.31
Peptide therapy for diabetes in NOD mice. Lancet (1994) 2.28
The use of gene fusions to study the expression of malT the positive regulator gene of the maltose regulon. J Mol Biol (1979) 2.27
Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Proc Natl Acad Sci U S A (1966) 2.25
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
Control of expression of the pyr genes in Salmonella typhimurium: effects of variations in uridine and cytidine nucleotide pools. J Bacteriol (1975) 2.24
The relationship between gastroesophageal reflux and apnea in infants. J Pediatr (2000) 2.24
Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci U S A (1990) 2.23
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
[Maltodextrin phosphorylase of Escherichia coli]. Eur J Biochem (1967) 2.21
Sequence information within the lamB genes in required for proper routing of the bacteriophage lambda receptor protein to the outer membrane of Escherichia coli K-12. J Mol Biol (1982) 2.20
Role of optical configuration in the immunogenicity and specificity of synthetic antigens derived from multichain polyproline. J Biol Chem (1968) 2.19
A single locus in the mouse encodes both myosin light chains 1 and 3, a second locus corresponds to a related pseudogene. Cell (1984) 2.19
Serum antibody response in experimental human gonorrhoea. Immunoglobulins G, A, and M. Br J Vener Dis (1969) 2.17
Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science (1988) 2.16
Postcholecystectomy biliary leaks in the laparoscopic era: risk factors, presentation, and management. McGill Gallstone Treatment Group. Gastrointest Endosc (1997) 2.15
Successful treatment of primary amebic meningoencephalitis. N Engl J Med (1982) 2.14
A technique for integrating any DNA fragment into the chromosome of Escherichia coli. Gene (1984) 2.11
Immunological studies with synthetic polypeptides. Adv Immunol (1966) 2.10
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc Natl Acad Sci U S A (1980) 2.07
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res (2000) 2.07
Phosphoglucomutase mutants of Escherichia coli K-12. J Bacteriol (1971) 2.07
Percutaneous dilational tracheostomy. A bedside procedure on the intensive care unit. Anaesthesia (1991) 2.07